(Q45252389)

11 December 2017

title

Cost-effectiveness of rituximab (MabThera) in diffuse large B-cell lymphoma in The Netherlands (English)

1 reference

cost-effectiveness analysis

11 December 2017

0 references

1 reference

1 reference

diffuse large B-cell lymphoma

1 reference

1 reference

Groot MT

1

1 reference

11 December 2017

Lugtenburg PJ

2

1 reference

11 December 2017

Hornberger J

3

1 reference

11 December 2017

Huijgens PC

4

1 reference

11 December 2017

Uyl-de Groot CA

5

1 reference

11 December 2017

publication date

1 March 2005

1 reference

European Journal of Haematology

11 December 2017

published in

1 reference

11 December 2017

volume

74

1 reference

11 December 2017

issue

3

1 reference

11 December 2017

page(s)

194-202

1 reference

Non-Hodgkin's lymphoma in the Netherlands: results from a population-based registry

11 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2004.00368.X

A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2004.00368.X

CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2004.00368.X

Cost analysis of CHOP (-like) chemotherapy regimens for patients with newly diagnosed aggressive non-Hodgkin's lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2004.00368.X

Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2004.00368.X

Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: results of the NHL-B1 trial of the DSHNHL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2004.00368.X

CHOP compared with CHOP plus granulocyte colony-stimulating factor in elderly patients with aggressive non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2004.00368.X

10.1111/J.1600-0609.2004.00368.X

21 January 2018

Identifiers

DOI

1 reference

11 December 2017

1 reference